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Abstract 
Purpose: To investigate the growth-inhibitory effect of 7-piperazinethylchrysin (PEC) on melanoma cell 
lines. 
Methods: Cell viability was analyzed by trypan blue exclusion assays and the cell cycle by flow 
cytometry using ModFit LT software. Specifically, cells were stained with propidium iodide (0.5 mg/mL) 
supplemented with RNase A (50 mg/mL), and analyzed using flow cytometry and ModFit LT software. 
Results: In A375 and B16F10 cell cultures, proliferation was reduced to 79 and 72 %, respectively, on 
treatment with 30 μM PEC. PEC increased the proportion of A375 cells in G1/G0 phase to 71.23 %, 
versus 42.76 % in untreated cells. In B16F10 and A375 cells, treatment with PEC caused the inhibition 
of Mek 1/2 kinase activity and suppressed Erk 1/2 phosphorylation. The level of cAMP-response 
element binding protein was increased by PEC. The expression of microphthalmia-linked transcription 
factor was also increased by PEC treatment. Marked enhancement was observed in the level of 
tyrosinase in melanoma cells on treatment with PEC. Analysis of PBG-D expression showed a marked 
increase in B16F10 and A375 cells on the addition of PEC to cell cultures at 72 h. The level of PBG D 
expression was increased by 9- and 8.5-fold in B16F10 and A375 cells, respectively, on incubation with 
30 μM PEC. The addition of a Mek 1/2 inhibitor (U0126) to the cultures promoted PEC-mediated growth 
inhibition. 
Conclusion: PEC inhibited melanoma cell proliferation, apparently by blocking the cell cycle at G0/G1 
and downregulating the Ras/Raf/Mek/Erk pathway.  
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Human melanoma is one of the most commonly 
detected malignant cancers of the skin, and its 
incidence is increasing worldwide [1]. Melanoma 
is detected mainly in females in the age group of 
25 – 29 years [2]. The average survival period for 
patients suffering from the metastatic stage of 
melanoma is only 7 months [3,4]. Currently, the 
primary treatment for melanoma consists of 
surgery [3,4]. The use of chemotherapeutic 
agents is limited because of the development of 
drug resistance [5]. 
 
Many skin problems, including the formation of 
wrinkles and appearance of dark spots, can be 
treated successfully by the application of natural 
products [6,7]. Thus, natural products may also 
offer novel therapeutic agents for the effective 
treatment of melanoma. 
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Flavonoids are an abundant class of natural 
products in plants, and biological investigations 
have revealed their promising potential as anti-
cancer agents [8]. Studies have demonstrated 
that flavonoids exhibit inhibitory effects, both in 
vitro and in vivo, on tumor cell proliferation in 
various types of cancers, including prostate, 
breast, and hepatic cancer cells [9]. 
 
An important advantage of flavonoids is their low 
toxicity in living systems. Thus, flavonoids are 
important candidates for the treatment of cancer. 
 
5, 7-Dihydroxyflavone, commonly known as 
chrysin, is a flavonoid isolated from extracts of 
many plants, including Passiflora caerulea, and 
propolis [10]. The biological properties of chrysin 
include anti-inflammatory, anti-oxidant, and anti-
cancer activities [11]. In cervical cancer and 
leukemia cells, chrysin treatment causes the 
induction of apoptosis [12]. In vivo studies have 
shown that chrysin prevents carcinoma 
metastasis by inhibiting tumor angiogenesis [13].  
 
A derivative of chrysin, 7-piperazinethylchrysin 
(PEC), is a potent anti-cancer agent against 
various carcinoma cell lines [14]. The current 
study was designed to investigate the effects of 





Reagents and test compound 
 
PEC was synthesized according to Edward et al 
[15]. The compound was dissolved in methanol 
to prepare a stock solution, which was diluted to 
provide solutions of the desired concentration. A 
specific inhibitor of Mek 1/2, U0126, was 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 
 
Cell lines and culture conditions 
 
The murine B16F1 melanoma cell line was 
purchased from the National Center for Cell 
Sciences; the A375 human melanoma cell line 
was obtained from the American Type Culture 
Collection (Manassas, VA, USA). Both lines were 
cultured in RPMI-1640 medium supplemented 
with 10 % fetal bovine serum. Cell culture was 
performed at 37 °C in a humidified atmosphere 
consisting of 5 % CO2 and 95 % air. 
 
Evaluation of cell viability  
 
A375 and B16F10 cells were grown in 24-well 
plates at a density of 2 × 105 cells per well and 
cultured for 24 h. Following culture, various 
concentrations of PEC, solvent, a combination of 
PEC and U0126, or U0126 were added to the 
wells, and the plates were incubated for 72 h. 
After incubation, the cells were washed, 
harvested, and subsequently subjected to 
trypsinization. Trypan blue solution (0.4 %) was 
then added to the wells followed by an 
examination of the cells under an optical 
microscope. The effects of PEC and U0126 on 
cell viability were compared with control cells 
treated with solvent alone. 
 
Cell cycle analysis 
 
The cells were distributed in 6-well plates at 3 × 
104 cells per well and cultured for 24 h. After 
incubation, the cells were treated for 72 h with 
various concentrations of PEC or solvent alone 
(control). The cells were then collected, washed 
with PBS, and subsequently fixed in 70 % ethyl 
alcohol. The cells were then stained with 
propidium iodide (PI; 0.5 mg/mL), supplemented 
with RNase A (50 mg/mL), and analyzed using 
flow cytometry and ModFit LT software (ver. 4.0; 
BD Biosciences, Franklin Lakes, NJ, USA). 
 
Determination of melanin formation 
 
A375 cells were seeded in 24-well plates at 2 × 
105 cells per well. After culture for 24 h, the cells 
were incubated with PEC or solvent for 72 h. 
After washing, the cells were collected and 
subjected to trypsinization. The cells were then 
centrifuged (700 × g, 20 min) to collect the 
supernatant for the determination of extracellular 
melanin. The supernatant (1 mL), after treatment 
with HEPES buffer (0.4 M, 6.8 pH) and 90 % 
ethyl alcohol, was subjected to optical density 
measurements at 476 nm. For the determination 
of intracellular melanin, treated cells were 
washed, trypsinized, and subsequently treated 
with 1 N NaOH. Melanogenesis was determined 
by the sum of the extracellular and intracellular 
melanin contents compared with control cells. 
 
Evaluation of tyrosinase activity 
 
After culture and incubation with PEC or solvent 
for 72 h, cells were collected, washed twice with 
PBS, and subjected to trypsinization. The cells 
were then treated with trypan blue (0.4 %). Cell 
lysates were prepared by treating the cells for 30 
min with a solution of Triton X-100 (1 %) in 
sodium phosphate buffer (0.1 M, 6.8 pH). 
Incubation of the lysates was performed for 4 h 
with DOPA (3, 4-dihydroxyphenylalanine) and 
sodium phosphate buffer. After incubation, the 
absorbance was recorded at 490 nm to measure 
the activity of tyrosinase as the fold increase in 
comparison with control cells. 
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Western blot analysis 
 
After treatment with PEC or solvent for 72 h, the 
cell lines were subjected to protein extraction on 
ice using lysis buffer (100 mM NaCl, 20 mM Tris 
HCl, pH 7.8, and 0.1 % NP-40). The cellular 
homogenates were subjected to centrifugation 
(10,000 rpm, 15 min, 4 °C) to obtain the 
supernatant, which was stored at -80°C until 
analysis. The total protein samples obtained 
were separated by 10 % SDS-PAGE and then 
transferred electrophoretically to nitrocellulose 
membranes. Blockage of non-specific sites on 
the membranes was performed at room 
temperature for 1 h using 2 % bovine serum 
albumin. Each membrane was incubated with 
primary antibodies overnight at 4 °C. The primary 
antibodies used were anti-p-Erk 1/2 (Tyr-204), 
anti-p-Mek 1/2 (Ser 218/Ser 222), anti-
microphthalmia related transcription factor (Mitf) 
(N-15), anti-p-cAMP-response element binding 
protein (CREB)-1 (Ser 133), and anti-PBG-D (A-
16) (all from Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). Following incubation, the 
membranes were washed and then incubated for 
1 h with horseradish peroxidase-conjugated 
secondary antibodies at room temperature. After 
washing, the blots were developed using an 
enhanced chemiluminescence kit (Amersham, 
Buckinghamshire, UK) and subjected to 




All data are presented as mean ± standard 
deviations. SigmaStat software (SPSS-Jandel 
2.0 Scientific, San Jose, CA, USA) was used for 
all statistical analyses. An analysis of the raw 
data was performed using the unpaired Student’s 
t-test. Among various doses, differences were 




PEC inhibited A375 and B16F10 cell 
proliferation 
 
In A375 cell cultures, the addition of PEC 
reduced proliferation by 12, 27, 36, 45, 63, and 
79 % at 5, 10, 15, 20, 25 and 30 μM, respectively 
(Figure 1). The proliferation of B16F10 cells was 
also reduced by PEC in a concentration-
dependent manner. B16F10 cell proliferation was 
reduced by 9, 18 29, 38, 59, and 72 % on 
treatment with 5, 10, 15, 20, 25 and 30 μM PEC, 
respectively, after 72 h. 
 
PEC induced cell cycle arrest in A375 and 
B16F10 cells 
 
Flow cytometry revealed that PEC increased the 
proportion of A375 cells in G1/G0 phase, with a 
consequent reduction in S phase (Figure 2). The 
proportion of A375 cells treated with 30 μM PEC 
in G1/G0 phase was increased to 71.23 % in 
comparison with 47.76 % in untreated cells. In S 
phase, the A375 cell proportion decreased, to 
11.09 %, on treatment with 30 μM PEC, relative 
to 29.67 % in untreated cells. In G2/M phase, the 
percentage of A375 cells was 15.89 and 21.46 % 
in cultures treated with 30 μM PEC and without 
treatment, respectively (Figure 2). Similar results 
were obtained with B16F10 cells (Figure 2). 
 
PEC altered Mek 1/2 activity in melanoma 
cells 
 
In A375 and B16F10 melanoma cell cultures, the 
addition of PEC caused a reduction in Erk 
phosphorylation after 72 h (Figure 3). The 
addition of 5, 10, 15, 20, 25 and 30 μM PEC to 
cultures of A375 cells reduced the Erk 
phosphorylation level in a concentration-




Figure 1: Effect of PEC on the rate of melanoma cell proliferation. Cells were treated with the indicated doses of 
PEC for 72 h followed by the determination of viability using trypan blue exclusion. The data are the means of 
triplicate experiments carried out independently; *p < 0.005 vs. untreated cell cultures 
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Figure 2: Effect of PEC on the cell cycle in melanoma cells. A375 and B16F10 cells were treated with PEC and 




Figure 3: Effect of PEC on the phosphorylation of Erk 1/2 and activation of Mek 1/2 in melanoma cells. A 
Western blot assay was used to analyze the phosphorylation of Erk 1/2 and activation of Mek 1/2 in (A) A375 and 




Figure 4: PEC promotes the formation of melanin and tyrosinase in A375 cells. The data are the means of three 
independent experiments; *p < 0.005, **p < 0.005 vs. solvent-treated cells 
 
Similarly, in B16F10 cells, the phosphorylation 
level was reduced on treatment with 5, 10, 15, 
20, 25 and 30 μM PEC. Mek 1/2 activation was 
promoted in both A375 and B16F10 cell cultures 
on the addition of PEC. Densitometry revealed 8, 
19, 47, 69, 72 and 91 % increases in the 
activation level of Mek 1/2 in A375 cell cultures 
on the addition of 5, 10, 15, 20, 25 and 30 μM 
PEC, respectively.  
 
Similarly, in B16F10 cell cultures, the addition of 
5, 10, 15, 20, 25 and 30 μM PEC enhanced the 
Mek 1/2 activation level to 6, 16, 43, 61, 74 and 
88 %, respectively (Figure 3A and Figure 3B). 
 
PEC promoted melanogenesis in melanoma 
cells 
 
In A375 cell cultures, incubation with PEC 
promoted the formation of melanin at 72 h 
(Figure 4). Melanin formation was increased by 
1.2, 1.9, 2.8, 3.6, 4.9 and 6-fold in A375 cells 
upon treatment with PEC at 5, 10, 15, 20, 25 and 
30 μM, respectively. Tyrosinase activity in A375 
cells was also promoted, by 1.8, 2.3, 2.7, 3.6, 3.9 
and 4-fold, on treatment with 5, 10, 15, 20, 25 
and 30 μM PEC, respectively (Figure 4). 
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PEC increased the phosphorylation of CREB 
and the expression of Mitf in melanoma cells 
 
In A375 cell cultures, the addition of PEC 
increased the CREB phosphorylation level at 72 
h. PEC addition at 5, 10, 15, 20, 25 and 30 μM 
increased the phosphorylation of CREB in a 
dose-based manner versus untreated cells 
(Figure 5A). The level of Mitf was also increased 
in A375 cells on treatment with PEC for 72 h. 
The increase was maximal at 30 μM PEC. 
Similar results were observed for CREB and Mitf 
in B16F10 cells (Figure 5B). 
 
PEC increased the level of porphobilinogen 
deaminase (PBG-D) in melanoma cells 
 
An analysis of the expression level of PBG-D 
protein showed a marked increase in A375 and 
B16F10 cells on the addition of PEC to cell 
cultures at 72 h. The level of PBG-D expression 
was increased, 2.0, 3.5, 4.6, 5.9, 7.6 and 9-fold, 
by 5, 10, 15, 20, 25 and 30 μM PEC in A375 
cells, respectively (Figure 6A). Similarly, in 
B16F10 cells, the addition of PEC to cultures 
increased the level of PBG-D at 5, 10, 15, 20, 25 
and 30 μM by 1.9, 3.1, 4.4, 5.3, 7.4 and 8.5-fold, 
respectively (Figure 6B). 
 
U0126 promoted the PEC-mediated inhibition 
of A375 and B16F10 cell proliferation 
 
In A375 cell cultures, the addition of PEC 
reduced cell growth by 79 % at 30 μM (Figure 7). 
Addition of the Mek 1/2 inhibitor U0126 
enhanced the PEC-mediated reduction in cell 
growth. PEC at 30 μM was added to cultures of 
A375 cells in combination with various 
concentrations of U0126. At 1, 2, 4, 6, 8 and 10 
μM U0126, in combination with PEC, cell viability 
was reduced by 83, 87, 89, 92, 93 and 96 %, 
respectively, versus the control (Figure 7). 
Similar results were observed for the inhibition of 





Figure 5: Effect of PEC on the phosphorylation of CREB and expression of Mitf in melanoma cells. (A) A375 and 
(B) B16F10 cells were treated with PEC for 72 h and then analyzed for changes in CREB phosphorylation and 




Figure 6: Effects of PEC on the PBG-D levels in melanoma cells. Cells treated with PEC were analyzed using 




Figure 7: Effect of the Mek 1/2 inhibitor U0126 on the PEC-mediated reduction in cell growth. Cells were treated 
with the indicated doses of U0126 and PEC followed by an analysis of cell viability. The data are the means of 
triplicate independent experiments; *p < 0.005 vs. untreated cell cultures 
Zeng et al 




In this study, we demonstrated the role of PEC in 
the inhibition of melanoma cell growth. The data 
show that PEC inhibited melanoma cell 
proliferation and blocked the cell cycle in G0/G1. 
 
The regulation of cellular processes, including 
viability, proliferation, and differentiation, via the 
transfer of signals from the cell to the nucleus, 
leading to cell cycle progression at G0/G1, is 
maintained by Erk 1/2, which belongs to the 
mitogen-activated protein kinase (MAPK) 
signaling pathway [16]. MAPK pathway 
regulation and Erk activation are dependent on 
Mek 1/2. The present study indicates that Erk 
phosphorylation was inhibited in melanoma cell 
lines upon treatment with PEC. PEC treatment 
also promoted the activation of Mek 1/2 in 
melanoma cells. Studies have shown that, 
among melanoma cells, more than 60 % harbor 
an activating mutation that induces Mek and Erk 
activation and consequently promotes the 
proliferation of cells and inhibits pigmentation 
[17]. 
 
The current study demonstrates that PEC 
treatment promoted melanogenesis in melanoma 
cells in a dose-dependent manner. Thus, PEC 
promoted Mek 1/2 activation, reducing its kinase 
activity and leading to the upregulation of 
melanogenesis through a cell cycle arrest. The 
formation of melanin in melanoma cells is 
induced via cAMP [18]. The activation and 
translocation of protein kinase A, and, 
consequently, CREB activation and gene 
transcription, are due to cAMP [19]. One of the 
genes expressed during this process is Mitf, 
which plays important roles in the regulation of 
melanocyte viability, proliferation, and 
differentiation [20]. 
 
Mitf is also involved in the transcription of 
tyrosinase-related genes, which are involved in 
melanogenesis induced by cAMP [21]. In the 
current study, PEC treatment significantly 
promoted the formation of melanin and the 
activity of tyrosinase in melanocytes. In 
melanoma cell lines, the addition of PEC 
increased the phosphorylation level of CREB. 
The level of Mitf was also increased in melanoma 
cells on treatment with PEC. Studies have shown 
that Erk 1/2 activation leads to the 
downregulation of Mitf expression [22]. Thus, the 
present study shows that PEC promoted the 
expression of Mitf and increased the CREB level 
by downregulating Erk 1/2 phosphorylation. In 
melanoma cells, Mitf mediated melanogenesis 
via an arrest of the cell cycle in G1/G0 phase. 
 
In the present study, PEC treatment inhibited the 
activity of Mek 1/2 kinase and phosphorylation of 
Erk, which play key roles in cell proliferation-
related gene transcription. Thus, it appears that 
PEC treatment causes stabilization of the cAMP 
signaling pathway in melanoma cells, 
phosphorylates CREB, and increases the level of 
Mitf, leading to the promotion of differentiation 
and melanogenesis. Our results show that 
U0126, in combination with PEC, enhanced the 
inhibition of melanoma cell proliferation. U0126 
inhibited cell viability, promoted melanoma cell 
differentiation, and inhibited tumor cell invasion 
[23]. Major factors that mediate the Raf signaling 
pathway include Mek 1 and Mek 2, which are 
considered to be of great value for 
downregulating the Raf/Mek/Erk pathway in 
carcinomas [23]. This study thus shows that 
U0126 downregulated the Ras/Raf/Mek/Erk 
pathway, which, in turn, increased the sensitivity 




PEC inhibited the proliferation of melanoma cells 
by blocking the cell cycle at G1/G0 phase and 
induced melanogenesis through Mek 1/2 
activation. Thus, PEC may be useful for the 
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